Novavax (NASDAQ:NVAX) had one of its worst days ever losing 34% on Thursday in the aftermath of two pieces of negative news that broke after Wednesday’s closing bell.
The vaccine maker was hit by the double whammy of announcing a $125M public offering of common stock and revealing that the UK was cutting in half a supply agreement for COVID shots.
On Wednesday, Novavax (NVAX) also reaffirmed its fiscal 2022 revenue guidance of ~$2B. Consensus is $2.01B.
READ FULL ARTICLE HERE
